enVVeno Medical Corporation

admin1702025-09-18 14:38:23

About enVVeno Medical Corporation

enVVeno Medical Corporation is a clinical-stage medical device company headquartered in Irvine, California, focused on developing bioprosthetic tissue-based solutions to improve the standard of care for venous disease treatment. Its lead product, VenoValve, is a replacement venous valve for chronic venous insufficiency, implanted into the femoral vein via open surgery. The company is also developing enVVe, a non-surgical, transcatheter-based replacement venous valve system, which includes the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and was renamed enVVeno Medical Corporation in October 2021.

Core Business & Key Technologies

enVVeno Medical Corporation specializes in research and development of medical devices for venous disease treatment. Its VenoValve product is surgically implanted to replace dysfunctional venous valves and address chronic venous insufficiency. The enVVe system provides a less invasive, transcatheter-based alternative, comprising a valve, delivery system, and accessories. The company also develops an innovative transcatheter pulmonary valve system for patients with pulmonary valve dysfunction, offering a minimally invasive option to improve outcomes and reduce recovery time.

Market Position & Flagship Products

The company’s flagship product, VenoValve, is currently being evaluated in the U.S. Surgical Antireflux Venous Valve Endoprosthesis (SAVVE) clinical trial. enVVe represents its non-surgical, transcatheter-based alternative for venous valve replacement. Both products aim to address critical unmet needs in chronic venous insufficiency treatment and minimally invasive cardiac care.

Recent Developments

In 2025, enVVeno Medical Corporation’s stock price experienced notable volatility. On August 19, it was $1.22, with a 52-week range of $1.15–$5.70, and dropped 16.12% to $4.19 on August 20. As of August 25, the stock closed at $4.19 with a trading volume of 613,654 shares. The company’s market capitalization was $14.15 million, with a levered free cash flow of -$9.11 million, net income of -$23.07 million, and diluted EPS of -$1.20. Forecasts project stock prices of $1.38 by 2030, $11.96 by 2040, and $13.39 by 2050.